Insight into the role of LCAT from mouse models

Reviews in Endocrine and Metabolic Disorders

Volumn 5, Issue 4, 2004, Pages 311-318

  Ng, Dominic S ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

atherosclerosis; glomerulosclerosis; glucose metabolism; high density lipoproteins; LCAT; lipogenesis; oxidation; triglyceride

Indexed keywords

HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; ENZYME ACTIVITY; GENE TRANSFER; GLOMERULOSCLEROSIS; GLUCOSE METABOLISM; HYPERTRIGLYCERIDEMIA; KIDNEY DISEASE; LIPID COMPOSITION; LIPOGENESIS; LIPOPROTEIN METABOLISM; MORBIDITY; MORTALITY; MOUSE STRAIN; NONHUMAN; OXIDATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; REVIEW;

ANIMALS; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; GLUCOSE; HUMANS; KIDNEY DISEASES; LIPOPROTEINS; LIPOPROTEINS, HDL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, ANIMAL; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; TRIGLYCERIDES;

EID: 6344257092     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:REMD.0000045102.70521.af     Document Type: Review

References (43)

1. Glomset JA. The mechanism of the plasma cholesterol esterification reaction: Plasma fatty acid transferase. Biochim Biophys Acta 1962;65:128-135.
2. Lacko AG, Pritchard PH. International Symposium on Reverse Cholesterol Transport. Report on a meeting. J Lipid Res 1990;31:2295-2299.
3. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 2003;92(4A):42J-49J.
4. Knight BL. ATP-binding cassette transporter A1: Regulation of cholesterol efflux. Biochem Soc Trans 2004;32(Pt 1):124-127.
5. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003;108:661-663.
6. Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard H, Frohlich J, Clerc M, Dumon MF, Fairwell T, Zech L. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest 1994;93:321-330.
7. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997;38:191-205.
8. Borysiewicz LK, Soutar AK, Evans DJ, Thompson GR, Rees AJ. Renal failure in familial lecithin: cholesterol acyltransferase deficiency. Q J Med 1982;51:411-426.
9. Santamarina-Fojo S, Lambert G, Hoeg JM, Brewer HB Jr. Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2000;11:267-275.
10. Francone OL, Gong EL, Ng DS, Fielding CJ, Rubin EM. Expression of human lecithincholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism. J Clin Invest 1995;96:1440-1448.
11. Mehlum A, Gjernes E, Solberg LA, Hagve TA, Prydz H. Overexpression of human lecithin: cholesterol acyltransferase in mice offers no protection against diet-induced atherosclerosis. APMIS 2000;108:336-342.
12. Furbee JW Jr, Parks JS. Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition. Atherosclerosis 2002;165:89-100.
13. Vaisman BL, Klein HG, Rouis M, Berard AM, Kindt MR, Talley GD, Meyn SM, Hoyt RF Jr, Marcovina SM, Albers JJ, Hoeg JM, Brewer B Jr, Santamarina-Fojo S. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem 1995;270:12269-12275.
14. Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, Paigen B, Hoyt RF Jr, Marcovina S, Brewer HB Jr, Santamarina-Fojo S. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med 1997;3:744-749.
15. Foger B, Chase M, Amar MJ, Vaisman BL, Shamburek RD, Paigen B, Fruchart-Najib J, Paiz JA, Koch CA, Hoyt RF, Brewer HB Jr, Santamarina-Fojo S. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem 1999;274:36912-36920.
16. Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W, Stengel D, Ninio E, Navab M, Mackness B, Mackness M, Holvoet P. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003;107:1640-1646.
17. Ng DS, Francone OL, Forte TM, Zhang J, Haghpassand M, Rubin EM. Disruption of the murine lecithin: cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J Biol Chem 1997;272:15777-15781.
18. Sakai N, Vaisman BL, Koch CA, Hoyt RF Jr, Meyn SM, Talley GD, Paiz JA, Brewer HB Jr, Santamarina-Fojo S. Targeted disruption of the mouse lecithin: cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J Biol Chem 1997;272:7506-7510.
19. Forte T, Nichols A, Glomset J, Norum K. The ultrastructure of plasma lipoproteins in lecithin: cholesterol acyltransferase deficiency. Scand J Clin Lab Invest Suppl 1974;137:121-132.
20. Lambert G, Sakai N, Vaisman BL, Nevfeld EB, Marteyn B, Chan C-C, Paigen B, Lupia E, Thomas A, Striker LJ, Blanchette-Mackie J, Csako G, Brady JN, Costello R, Striker GE, Remaley AT, Brewer B Jr, Santamarina-Fojo S. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem 2001;276:15090-15098.
21. Furbee JW Jr, Sawyer JK, Parks JS. Lecithin: cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem 2002;277:3511-3519.
22. Ng DS, Maguire GF, Wylie J, Ravandi A, Xuan W, Ahmed Z, Eskandarian M, Kuksis A, Connelly PW. Oxidative stress is markedly elevated in lecithin: cholesterol acyltransferasedeficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis. J Biol Chem 2002;277:11715-11720.
23. Forte TM, Oda MN, Knoff L, Frei B, Suh J, Harmony JA, Stuart WD, Rubin EM, Ng DS. Targeted disruption of the murine lecithin: cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. J Lipid Res 1999;40:1276-1283.
24. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999;19:2214-2225.
25. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-287.
26. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002;106:484-490.
27. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: Studies in PON1-knockout mice. Free Radic Biol Med 2003;34:774-784.
28. Furbee JW Jr, Francone O, Parks JS. In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL receptor and apolipoprotein E knockout mice. J Lipid Res 2002;43:428-437.
29. Zhao Y, Thorngate FE, Weisgraber BCH, Williams DL, Parks JS. Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase on apolipoproteins B lipoprotein particles. Arteriosclerol Thromb Vasc Biol 2004;P461.
30. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003;115(Suppl 8A):24S-28S.
31. Kodama T, Akanuma Y, Okazaki M, Aburatani H, Itakura H, Takahashi K, Sakuma M, Takaku F, Hara I. Abnormalities in plasma lipoprotein in familial partial lecithin: cholesterol acyltransferase deficiency. Biochim Biophys Acta 1983;752:407-415.
32. Frohlich J, McLeod R, Pritchard PH, Fesmire J, McConathy W. Plasma lipoprotein abnormalities in heterozygotes for familial lecithin: cholesterol acyltransferase deficiency. Metabolism 1988;37:3-8.
33. Hoeg JM, Vaisman BL, Demosky SJ Jr, Meyn SM, Talley GD, Hoyt RF Jr, Feldman S, Berard AM, Sakai N, Wood D, Brousseau ME, Marcovina S, Brewer HB Jr, Santamarina-Fojo S. Lecithin: cholesterol acyltransferase overexpression generates hyperalphalipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem 1996;271:4396-4402.
34. Blomhoff JP, Holme R, Sauar J, Gjone E. Familial lecithin: cholesterol acyltransferase deficiency. Further studies on plasma lipoproteins and plasma postheparin lipase activity of a patient with normal renal function. Scand J Clin Lab Invest Suppl 1978;150:177-182.
35. Ng DS, Xie C, Maguire GF, Zhu X, Ugwu F, Lam E, Connelly PW. Hypertriglyceridemia in lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of triglycerides, increased lipogenesis, and improved glucose tolerance. J Biol Chem 2004;279:7636-7642.
36. Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, Zhang Y, Stayrook KR, Suen C, Otto KA, Miller AR, Dai J, Foxworthy P, Gao H, Ryan TP, Jiang XC, Burris TP, Eacho PI, Etgen GJ. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 2003;278:1131-1136.
37. Pawar A, Botolin D, Mangelsdorf DJ, Jump DB. The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression. J Biol Chem 2003;278:40736-40743.
38. Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, Ishibashi S, Osuga J, Yamada N, Shimano H. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003;38:1529-1539.
39. Field FJ, Born E, Murthy S, Mathur SN. Polyunsaturated fatty acids decrease the expression of sterol regulatory element-binding protein-1 in CaCo-2 cells: Effect on fatty acid synthesis and triacylglycerol transport. Biochem J 2002;368:855-864.
40. Santamarina-Fojo S, Hoeg JM, Assmann G, Bryan Brewer H Jr. Lecithin cholesterol acyltransferase deficiency and fish eye disease. In: Scriver CR, Beaudet AL, Sly WS, et al. The Metabolic and Molecular Bases of Inherited Disease (8th ed.). New York: McGraw-Hill, 2001:2817-2833.
41. Lynn EG, Siow YL, Frohlich J, Cheung GT, O K. Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B. Kidney Int 2001;60:520-532.
42. Zhu X, Herzenberg AM, Eskandrian M, Maguire GF, Scholey JW, Connelly PW, Ng DS. A novel in vivo lecithin-cholesterol acyltransferase (LCAT) deficient mouse expressing predominantly LpX is associated with spontaneous glomerulopathy. Am J Path 2004; in press.
43. Massey AR, Miao L, Smith BN, Liu J, Kusaka I, Zhang JH, Tang J. Increased RhoA translocation in renal cortex of diabetic rats. Life Sci 2003;72:2943-2952.